# Stage 21H Synthetic Runtime Acceptance Decision

Stage 21H is prepared as an acceptance and closure decision only. It may accept the minimal
local serving architecture solely as a research-only, synthetically validated capability.
It cannot authorize persistent operation, real model loading or inference, GPU residency
profiling, patient processing, locked-test access, or language-model work.

Acceptance preserves the three frozen endpoints, sequential single-model GPU architecture,
deterministic CPU post-processing, request isolation, sanitized failures, DEFER versus
FAILED_SANITIZED semantics, and every upstream safety limitation. It does not establish
clinical correctness, production readiness, deployment readiness, or autonomous use.

If accepted, the next canonical stage is Stage 22A research UI and medical-viewer data
readiness. Stage 22A remains audit-only and does not authorize model loading, inference,
GPU profiling, real patient processing, or LLM work. No LLM-authorized gate is scheduled in
the canonical roadmap.
